scholarly journals Cotransplantation of Mesenchymal Stem Cells With Neonatal Porcine Islets Improve Graft Function in Diabetic Mice

Diabetes ◽  
2017 ◽  
Vol 66 (5) ◽  
pp. 1312-1321 ◽  
Author(s):  
Julie A. Hayward ◽  
Cara E. Ellis ◽  
Karen Seeberger ◽  
Timothy Lee ◽  
Bassem Salama ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Function ◽  
Diabetic Mice ◽  
Porcine Islets ◽  
Neonatal Porcine Islets

scholarly journals The tissue origin of human mesenchymal stem cells dictates their therapeutic efficacy on glucose and lipid metabolic disorders in type II diabetic mice

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yinzhong Ma ◽  
Lisha Wang ◽  
Shilun Yang ◽  
Dongyu Liu ◽  
Yi Zeng ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Therapeutic Efficacy ◽  
Metabolic Disorders ◽  
Human Mscs ◽  
Dependent Manner ◽  
Type Ii ◽  
Diabetic Mice ◽  
Histological Lesion ◽  
Insulin Levels

Abstract Background The therapeutic efficacy of mesenchymal stem cells (MSCs) of different tissue origins on metabolic disorders can be varied in many ways but remains poorly defined. Here we report a comprehensive comparison of human MSCs derived from umbilical cord Wharton’s jelly (UC-MSCs), dental pulp (PU-MSCs), and adipose tissue (AD-MSCs) on the treatment of glucose and lipid metabolic disorders in type II diabetic mice. Methods Fourteen-to-fifteen-week-old male C57BL/6 db/db mice were intravenously administered with human UC-MSCs, PU-MSCs, and AD-MSCs at various doses or vehicle control once every 2 weeks for 6 weeks. Metformin (MET) was given orally to animals in a separate group once a day at weeks 4 to 6 as a positive control. Body weight, blood glucose, and insulin levels were measured every week. Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed every 2 weeks. All the animals were sacrificed at week 6 and the blood and liver tissues were collected for biochemical and histological examinations. Results UC-MSCs showed the strongest efficacy in reducing fasting glucose levels, increasing fasting insulin levels, and improving GTT and ITT in a dose-dependent manner, whereas PU-MSCs showed an intermediate efficacy and AD-MSCs showed the least efficacy on these parameters. Moreover, UC-MSCs also reduced the serum low-density lipoprotein cholesterol (LDL-C) levels with the most prominent potency and AD-MSCs had only very weak effect on LDL-C. In contrast, AD-MSCs substantially reduced the lipid content and histological lesion of liver and accompanying biomarkers of liver injury such as serum aspartate transaminase (AST) and alanine aminotransferase (ALT) levels, whereas UC-MSCs and PU-MSCs displayed no or modest effects on these parameters, respectively. Conclusions Taken together, our results demonstrated that MSCs of different tissue origins can confer substantially different therapeutic efficacy in ameliorating glucose and lipid metabolic disorders in type II diabetes. MSCs with different therapeutic characteristics could be selected according to the purpose of the treatment in the future clinical practice.

scholarly journals Role of the autologous mesenchymal stem cells compared with platelet rich plasma on cicatrization of cutaneous wounds in diabetic mice

2016 ◽  
Vol 36 (7) ◽  
pp. 617-624
Author(s):  
Napoleão M. Argolo Neto ◽  
Ricardo J. Del Carlo ◽  
Betânia S. Monteiro ◽  
Nance B. Nardi ◽  
Pedro C. Chagastelles ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Platelet Rich Plasma ◽  
Cutaneous Lesion ◽  
Healing Time ◽  
Diabetic Mice ◽  
Cutaneous Lesions ◽  
Cutaneous Wounds ◽  
Autologous Mesenchymal Stem Cells ◽  
Treatment Of Wounds

Abstract: Chronic cutaneous lesions affect 15% of diabetic human patients and represent a risk 15 to 46 times larger of limb amputations compared to people with normal glycemia. It is assumed that half of these amputations could be prevented by early treatment of wounds, for example, with proper cell therapy. Objectives: In this study, the action of the autologous transplant of mesenchymal stem-cells (MSC) was evaluated compared to the treatment with autologous platelet rich plasma (PRP) in the cicatrization of cutaneous lesions induced in diabetic mice. These animals were previously treated with streptozootocin to induce diabetes mellitus and round wounds of 1.5cm in diameter were created in the posterior region. Diameters of the wounds and healing time were evaluated during 30 days and the results were submitted to variance analysis and Tukey's test average. It was noticed that the animals treated with MSC presented a more accelerated cicatrization of the cutaneous lesion than the animals treated with PRP. However, the treatment with PRP presented better results than just the daily asepsis of the lesions with saline or covering them with semi-permeable bandage. Besides, the use of semi-permeable bandage kept the cutaneous lesions of diabetic mice did not interfere negatively with cicatrization, proved to be harmless to use, but kept the cutaneous lesions more hydrated than the ones exposed to the environment.

Bone marrow mesenchymal stem cells promote the repair of islets from diabetic mice through paracrine actions

2014 ◽  
Vol 388 (1-2) ◽  
pp. 41-50 ◽  
Author(s):  
Xiaodong Gao ◽  
Lujun Song ◽  
Kuntang Shen ◽  
Hongshan Wang ◽  
Mengjia Qian ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Diabetic Mice ◽  
Marrow Mesenchymal Stem Cells ◽  
Paracrine Actions

Transplantation of Microencapsulated Syngeneic and Xenogeneic (Neonatal Porcine) Islets in Nonobese Diabetic Mice

1998 ◽  
Vol 30 (2) ◽  
pp. 500 ◽  
Author(s):  
Z Ao ◽  
W.L Suarez-Pinzon ◽  
R.V Rajotte ◽  
G.S Korbutt ◽  
M Flashner ◽  
...  
Keyword(s):  
Diabetic Mice ◽  
Porcine Islets ◽  
Nonobese Diabetic ◽  
Nonobese Diabetic Mice ◽  
Neonatal Porcine Islets

scholarly journals Induction Therapy With Mesenchymal Stem Cells in Kidney Transplantation: A Meta-Analysis

2020 ◽  
Author(s):  
Lingfei Zhao ◽  
Chenxia Hu ◽  
Fei Han ◽  
Dajin Chen ◽  
Jun Cheng ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Kidney Transplantation ◽  
Opportunistic Infection ◽  
Infection Rate ◽  
Induction Therapy ◽  
Meta Analysis ◽  
Graft Function ◽  
Renal Graft ◽  
Post Surgery

Abstract Objective The aim of this meta-analysis was to evaluate the therapeutic effects of mesenchymal stem cells (MSCs) versus other regimens as induction therapy in kidney transplantation patients.Methods PubMed, Embase, EBSCO, Ovid and the Cochrane Library were searched to identify prospective clinical trials which compared MSCs with other regimens as induction therapy in renal allograft.Results Four studies with five cohorts were contained, including a total of 301 patients. The pooled results revealed that the MSCs therapy had a lower 1-year infection rate (RR=0.73, 95% CI: 0.58–0.93, P=0.01), espeicially for 1-year opportunistic infection rate (RR=0.59, 95% CI: 0.37–0.93, P=0.02). There were no significant differences between the two protocols regarding 1-year acute rejection (AR) rate (RR=0.69, 95% CI: 0.42–1.14, P=0.15), 1-year graft survival rate (RR=0.99, 95% CI: 0.95–1.03, P=0.74), delayed graft function (DGF) rate (RR=0.72, 95% CI: 0.34–1.50, P=0.38) and renal graft function at 1 month (MD=2.4, 95% CI: -7.41– 12.22, p=0.63), 3 months (MD=0.91, 95% CI: -4.17– 5.98, p=0.73), 6 months (MD=-1.41, 95% CI: -5.69– 2.87, p=0.52), 12 months (MD=1.25, 95% CI: -3.89– 6.4, p=0.63) post surgery. Subgroup analysis demonstrated 1-year AR rate, DGF rate and renal graft function at 12 month post surgery did not reach to a significant difference between low-dose calcineurin inhibitors (CNIs) group with standard-dose CNIs group, indicating successful CNIs withdrawal in combination with MSCs treatment. Meanwhile, when applied MSCs as an alternative standard induction therapy regimen, all of those outcomes mentioned above were also comparable with those in MSCs plus standard induction therapy group.Conclusion Induction therapy of MSCs has similar inducing immune tolerance effects on the recipients in kidney transplantation compared with that of other regimens. However, regarding the long term effect, as represented by 1-year infection rate, 1-year opportunistic infection rate and CNIs withdrawl, MSCs therapy has a significant advantage.

Sign in / Sign up

Export Citation Format

Share Document